PFE · 8-K · 20260804PR000094

Headcount / Restructuring

PFIZER INC · 2026-08-04 · Importance 52 · Surprise 42 · In source text

Pfizer announced approximately $1.0 billion of additional anticipated net savings from its ongoing Realigning Our Cost Base Program, expected to be realized from 2027 through 2029 through technology and simplification efforts across commercial, R&D and enabling functions. One-time costs to achieve these savings are expected to total approximately $2.0 billion through 2029, primarily for digital enablement, implementation and severance. Including prior savings, Pfizer expects approximately $6.7 billion of cumulative net savings from the program through 2029. Separately, the next phase of its Manufacturing Optimization Program is expected to generate approximately $1.5 billion of additional savings through 2029, with approximately $4.0 billion of one-time costs, including 60% non-cash expenditures and 40% cash expenditures.

Key facts

• Announces additional anticipated productivity enhancement savings of $2.5 billion expected to be realized from 2027 through 2029 source
• Pfizer expects total net cost savings of approximately $6.7 billion from the Realigning our Cost Base Program through 2029 (including approximately $5.7 billion by end of 2026 plus $1.0 billion additional) source
• Pfizer announced $1.0 billion of additional anticipated net cost savings in SI&A from the Realigning Our Cost Base Program to be realized from 2027 through 2029, with one-time costs to achieve the additional savings expected to total approximately $2.0 billion source
• Finance leadership change: Dave Denton will step down as CFO and leave on August 15; Cecile Guegan named Interim CFO effective August 16, 2026 source

Impact estimates